Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact

Shares of top 1% biotech stock Tango Therapeutics (TNGX) shot to a nearly five-year high Thursday after the company agreed to codevelop a cancer treatment with Erasca (ERAS).

The pact will see Tango’s vopimetostat combined with ERAS-0015. Vopimetostat blocks PRMT5, an enzyme that regulates gene expression, splicing and cell signaling. It’s also a known cancer driver. ERAS-0015 is a “molecular glue” that inhibits another cancer driver, the RAS protein.

				    ↑
					X

This video file cannot be played.(Error Code: 102630)

								These Three Catalysts Could Make Medical Stocks A Healthy Bet In 2026
							

							

								See All Videos
							

						

					
					
						NOW PLAYING
						These Three Catalysts Could Make Medical Stocks A Healthy Bet In 2026

Previously, Tango tapped Revolution Medicines (RVMD) to test out vopimetostat with another set of RAS-blocking drugs. Revolution, in turn, has a partnership with Bristol Myers Squibb (BMY) for its Tango-rivaling PRMT5 blockers.

The increasing number of deals suggests combining drugs that block PRMT5 and RAS could pay off in certain cancers, Leerink Partners analyst Andrew Berens said in a report.

“Overall, we think it is prudent for both companies to pursue as many shots on goal as possible, and the fact that both TGNX and RVMD are expanding the breadth of their PRMT5 + RAS combination programs suggests the early signals are favorable,” he said.

He rates Tango Therapeutics stock an outperform.

Biotech Stock Soars Over 2026

Tango stock has been on a run recently, rising 39% this year, as of Wednesday’s close. In afternoon trades on today’s stock market, the biotech stock surged more than 25% to 15.50, hitting its highest point since September 2021.

Shares have a best-possible IBD Digital Relative Strength Rating of 99, meaning Tango Therapeutics stock has performed in the leading 1% of all stocks over the past 12 months.

Its Composite Rating — a 1-99 score of fundamental and technical measures — is lower, however, at 83. This puts the biotech stock in the top 17% of all stocks on that metric.

IBD Newsletters

Get exclusive IBD analysis and actionable news daily.

		SIGN UP NOW!

IBD Newsletters

Get exclusive IBD analysis and actionable news daily.

										*   							
								How To Invest								
								
							
						
										*   							
								Market Prep								
								
							
						
										*   							
								Tech Report								

Please enter a valid email address

Please select a newsletter

			GO

Get these newsletters delivered to your inbox & more info about our products & services. Privacy Policy & Terms of Use

		x

Thank You!

You will now receive IBD Newsletters

			ALL DONE!

Something Went Wrong!

Please contact customer service

			CLOSE

Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.

YOU MAY ALSO LIKE:

Moderna Stock Pops After Inking $950 Million Covid Vaccine Settlement

Why Harrow, An IBD 50 Stock Up 32% Since January, Just Crashed

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Options Trading: How To Start Using Options, How To Manage Risk

Get Timely Buy & Sell Alerts With IBD Leaderboard